Over the past decade, clinical trials have notoriously become plagued by problematic protocols, missed enrollment targets, and an unsettling level of redundancy and rework. Only about a third of drugs that enter clinical testing ever progress to large-scale phase III studies and success rate could decline further if healthcare reform moves up the norm for proving value over therapeutic alternatives. Life sciences companies forced